ArticleJournal of thoracic disease2019
Intermediate-term outcomes after aortic valve replacement with a novel RESILIA
Article in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early and late clinical outcomes and cost-effectiveness of aortic valve replacement using the Inspiris Resilia bioprosthesis : A systematic review and meta-analysis.Journal of cardiothoracic surgery · 2025Pooled it
- Clinical Outcomes of a New-Generation Surgical Aortic Bioprosthesis: A Noninferiority Study.JTCVS open · 2026Article
- A protocol of 'A post-market national POLish registry of biological prostheses with RESilia tissue (POLRES)'.Cardiology journal · 2025Article
- Comparison of four aortic bioprostheses: Hancock IIJournal of thoracic disease · 2024Article
- Case Series of First Microinvasive Fully Endoscopic Use of a New Mitral Prosthesis.Journal of clinical medicine · 2024Article
- Five-year outcomes of surgical aortic valve replacement with a novel bovine pericardial bioprosthesis.Interdisciplinary cardiovascular and thoracic surgery · 2024Article
- Durability of bioprosthetic aortic valve replacement in patients under the age of 60 years - 1-year follow-up from the prospective INDURE registry.Interdisciplinary cardiovascular and thoracic surgery · 2023Article
- Valve-in-Valve TAVR versus Redo Surgical Aortic Valve Replacement: Early Outcomes.The Thoracic and cardiovascular surgeon · 2023Article
- One-year clinical outcomes following Edwards INSPIRIS RESILIA aortic valve implantation in 487 young patients with severe aortic stenosis: a single-center experience.Frontiers in cardiovascular medicine · 2023Article
- Early experience with the ThopazKardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2021Article
- Bioprosthetic or mechanical heart valves: prosthesis choice for borderline patients?-Results from 9,616 cases recorded in Polish national cardiac surgery registry.Journal of thoracic disease · 2020Article
- Durability of bioprosthetic aortic valves in patients under the age of 60 years - rationale and design of the international INDURE registry.Journal of cardiothoracic surgery · 2020Article
- Systematic review and meta-analysis of surgical outcomes comparing mechanical valve replacement and bioprosthetic valve replacement in infective endocarditis.Annals of cardiothoracic surgery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe durability of bioprosthetic heart valves is limited by structural valve deterioration (SVD) due to long-term calcification. A novel bioprosthetic tissue (RESILIA
methodsA prospective, single-arm, observational trial was conducted in patients who required surgical aortic valve replacement (AVR). Between July 2011 and February 2013, 133 patients were implanted at two sites in Poland. Hemodynamic performance and clinical outcomes were assessed annually through 4 years of follow-up. All safety events were adjudicated by an independent Clinical Events Committee, and echocardiographic data were evaluated by a core laboratory.
resultsPatients were 65.3±13.5 years old and 26% were ≤60 years old. The average follow-up was 3.8±1.1 (median: 4.1; IQR, 4.0-4.3) years. Early (≤30 day) and late (>30 day) all-cause mortality rates were 2.3% (n=3) and 3.2% late patient-years (n=16), respectively. There were no cases of early or late SVD. There was one early case of major paravalvular leak (0.8%), and no late cases. At 4 years, the mean gradient was 14.5±7.4 mmHg and the effective orifice area was 1.6±0.4 cm
conclusionsThe aortic bioprosthesis with novel RESILIA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.